Lurbinectedin is a chemotherapy drug that has been studied in clinical trials for the treatment of various types of cancer. According to the sources provided, several clinical trials have investigated the use of lurbinectedin in combination therapies.

One such trial is NCT02611024, which is a phase 1b/2 study of lurbinectedin in combination with doxorubicin in patients with advanced solid tumors. The trial aims to evaluate the safety and efficacy of the combination therapy and determine the recommended dose for further studies [2].

Another trial is C82382, which is a phase 2 study of lurbinectedin in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. The trial aims to evaluate the efficacy of the combination therapy in terms of overall response rate and progression-free survival [3].

Furthermore, DrugPatentWatch reports that several patents have been filed for lurbinectedin in combination with other drugs, including platinum-based compounds, taxanes, and topoisomerase inhibitors [1].

In conclusion, several clinical trials have investigated the use of lurbinectedin in combination therapies for the treatment of cancer. These trials have evaluated the safety and efficacy of lurbinectedin in combination with other chemotherapy drugs and immunotherapy agents. However, further research is needed to determine the optimal combination therapies for different types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.clinicaltrials.gov/ct2/show/NCT02611024
[3] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382